RxDoctor Payments Data

Michael Nagel, MD

Neurology with Special Qualifications in Child Neurology · Toledo, OHNPI 1912999350

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,855 of the $8,813 with a category attached, or 89.1%. It is spread thinly across 60 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations.

$8,813in general payments, 2019–2025

Across 469 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$2K
  • UCB, Inc.$892
  • Neurelis, Inc.$774
  • SK Life Science, Inc.$473
  • AbbVie$380
  • Teva Pharmaceuticals USA, Inc.$310
  • plus $4K from 54 others

What the payments were for

  • Travel & lodging$88110%
  • Food & beverage$7,85589%
  • Education$781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Livanova USA, Inc.58$1,638
UCB, Inc.47$892
Neurelis, Inc.29$774
SK Life Science, Inc.21$473
AbbVie(2 entities)21$380
Teva Pharmaceuticals USA, Inc.20$310
AstraZeneca(2 entities)14$291
Biogen16$271
EMD Serono, Inc.32$247
Eisai Inc.15$246
Piramal Critical Care15$232
Aquestive Therapeutics, Inc.15$224
Biocodex, Inc.6$179
Jazz Pharmaceuticals Inc.7$148
Genentech USA, Inc.8$148
Novartis10$147
Amgen(2 entities)9$137
Acadia Pharmaceuticals Inc9$127
Catalyst Pharmaceuticals, Inc.6$116
Biomarin Pharmaceutical Inc.1$113
Lilly USA, LLC8$111
Neurocrine Biosciences, Inc.6$108
Lundbeck LLC6$96
Argenx US, Inc.5$94
CSL Behring5$88
ITF Therapeutics LLC3$68
Sunovion Pharmaceuticals Inc.6$65
Supernus Pharmaceuticals, Inc.5$62
Kyowa Kirin, Inc.4$61
Biohaven Pharmaceutical Holding Company Ltd.3$58
Avanir Pharmaceuticals, Inc.3$53
NS Pharma, Inc.3$53
Amneal Pharmaceuticals LLC4$52
Pfizer3$49
TG Therapeutics, Inc.2$45
Otsuka America Pharmaceutical, Inc.2$43
Tersera Therapeutics LLC2$40
Tanabe Pharma America, Inc.3$40
Sanofi2$39
Alnylam Pharmaceuticals Inc.2$35
Bristol Myers Squibb2$30
Xeris Pharmaceuticals, Inc.2$30
Akcea Therapeutics, Inc.2$29
Mallinckrodt Enterprises LLC2$28
Upsher-smith Laboratories LLC2$28
Nevro Corp.1$27
PTC Therapeutics, Inc.2$26
Sarepta Therapeutics, Inc.1$26
Biohaven Pharmaceuticals, Inc.1$25
E.r. Squibb & Sons, L.L.C.2$25
Merz Pharmaceuticals, LLC1$24
Johnson & Johnson1$18
Axsome Therapeutics, Inc.1$17
Saol Therapeutics Inc.1$17
Acorda Therapeutics, Inc1$15
Bausch Health US, LLC1$15
Aprecia Pharmaceuticals, LLC1$14
Takeda Pharmaceuticals U.S.A., Inc.1$14
Aucta Pharmaceuticals, Inc.1$13
Zogenix Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,813 in reported general payments places this provider in the 75th percentile of 113 neurology with special qualifications in child neurology providers in Ohio.

See all neurology with special qualifications in child neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$4,679
Medicare patients
15
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)14$139,782
DiacomitStiripentol12$104,473
BanzelRufinamide19$59,311
XifaxanRifaximin12$38,578
XcopriCenobamate15$26,103
BriviactBrivaracetam13$17,155
LamictalLamotrigine12$14,847
KeppraLevetiracetam11$11,148
Lacosamide20$10,420
Depakote ErDivalproex Sodium14$6,567
Oxcarbazepine24$5,980
CelontinMethsuximide11$2,653
Levetiracetam55$1,987
Clobazam23$1,652
Baclofen71$1,557

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Biocodex, Inc.Diacomit$179$104,47312 claims
Eisai Inc.Banzel$246$59,31119 claims
SK Life Science, Inc.Xcopri$473$26,10315 claims
UCB, Inc.Briviact$892$17,15513 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$52$78114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 113 neurology with special qualifications in child neurology providers in Ohio.

Other neurology with special qualifications in child neurology in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →